Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
International Journal of Clinical Oncology, 05/01/2012

Nakamura K et al. – The clinical effect of the combination of platinum and anthracycline for metastatic cutaneous squamous cell carcinoma (CSCC) was limited despite the findings of two patients showing durable complete responses.

• The authors retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC.

• Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each.
• The combination regimens were as follows: cisplatin (CDDP) (60–90mg/m²/day, day 1) and adriamycin (ADM) (20–40mg/m²/day, day 1 or 2) was administered in 5 patients; CDDP (10–15mg/m²/day, days 1–5) and epirubicin (epi-ADM) (10–15mg/m²/day, days 1–5) was administered in 2 patients; and carboplatin (CBDCA) (200–400mg/m²/day, day 1) and ADM (20–40mg/m²/day, day 1 or 2) was administered in one patient.
• The responses were as follows: complete response in 2 patients (CDDP+ADM for lung metastasis, CDDP+epi-ADM for lymph node metastasis), partial response in 1 (CDDP+ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3.
• A durable response was observed in 2 patients showing complete responses (58 and 112months).